バイオバンク市場- 世界の産業規模、シェア、動向、競合、機会、予測、タイプ別、サンプルタイプ別、用途別、エンドユーザー別、地域別、競合別、2019年～2029年

世界のバイオバンク市場は、2023年に753億4,000万米ドルと評価され、2029年までのCAGRは8.54%で、予測期間中に力強い成長が予測されています。

世界のバイオバンク市場は、研究、臨床試験、個別化医療構想のための高品質な生物学的サンプルに対する需要の増加により、大幅な成長を遂げています。バイオバンクは、血液、組織、細胞、DNAなどさまざまな種類の生物学的検体を、病歴や生活習慣などの関連データとともに保存するための保管庫として機能します。これらのバンクは、生物医学研究を推進する上で重要な役割を担っており、科学者が大規模かつ多様なサンプル・コレクションにアクセスすることで、疾患の研究、バイオマーカーの同定、新たな治療薬の開発が可能になります。世界のバイオバンク市場の成長を促進する主な要因の1つは、がん、心血管障害、神経疾患などの慢性疾患の有病率の上昇です。多様な患者集団から十分に特性化され、注釈付けされた生物試料の必要性は、疾患メカニズムの理解、新規治療標的の発見、治療反応の評価に不可欠です。さらに、自動化、ロボット工学、データ管理システムなどのバイオバンキング技術の進歩により、バイオバンキング業務の効率性、拡張性、質が向上しています。プレシジョン・メディシン（精密医療）アプローチや個別化ヘルスケア戦略の採用が増加していることから、詳細な分子生物学的・臨床的注釈が付された生物試料の需要が高まっています。バイオバンクは、遺伝子型-表現型相関、薬理ゲノミクス研究、患者層別化の取り組みのための包括的なサンプルコレクションへのアクセスを研究者や臨床医に提供することで、精密医療の取り組みを支援する上で極めて重要な役割を果たしています。その結果、世界のバイオバンク市場は継続的な拡大が見込まれており、バイオバンク機関、ヘルスケア機関、ライフサイエンス企業にとって、生物医学研究や治療法の革新に貢献する重要な機会を提供しています。

主な市場促進要因

高品質生体サンプルに対する需要の高まり

バイオバンキング技術の進歩

慢性疾患の増加

主な市場課題

サンプルの品質と完全性

データ管理と統合

主要市場動向

疾患によるバイオバンクの拡大

バーチャルバイオバンクへのシフト

セグメント別洞察

タイプ別洞察

用途別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のバイオバンク市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別（疾患指向バイオバンク、集団ベースバイオバンク、組織バイオバンク、その他）
  • サンプルタイプ別（血液製品、体液、核酸、細胞株、その他）
  • 用途別（治療薬、創薬、臨床診断、臨床研究）
  • エンドユーザー別（学術研究機関、製薬バイオテクノロジー企業、病院クリニック、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • タイプ別
  • サンプルタイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 アジア太平洋地域のバイオバンク市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • サンプルタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第7章 欧州のバイオバンク市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • サンプルタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • 英国
  • イタリア
  • ドイツ
  • スペイン

第8章 北米のバイオバンク市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • サンプルタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第9章 南米のバイオバンク市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • サンプルタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのバイオバンク市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • サンプルタイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品発表
• 合併・買収

第13章 バイオバンクの世界市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 企業プロファイル

• Danaher Corporation
  • 事業概要
  • 会社概要
  • 製品サービス
  • 財務（上場している場合）
  • 最近の動向
  • SWOT分析
• Merck KGaA
• Becton, Dickinson, and Company
• Avantor, Inc.
• Thermo Fisher Scientific, Inc
• Tecan Trading AG
• QIAGEN N.V.
• Hamilton Company
• ProMedDx, LLC
• ISENET Biobanking S.r.l

第16章 戦略的提言

第17章 免責事項

Global Biobanks Market was valued at USD 75.34 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.54% through 2029. The Global Biobanks Market is experiencing substantial growth driven by increasing demand for high-quality biological samples for research, clinical trials, and personalized medicine initiatives. Biobanks serve as repositories for storing various types of biological specimens, including blood, tissues, cells, and DNA, along with associated data such as medical histories and lifestyle information. These repositories play a crucial role in advancing biomedical research, enabling scientists to access large and diverse collections of samples for studying diseases, identifying biomarkers, and developing new therapeutics. One of the key drivers fueling the growth of the Global Biobanks Market is the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. The need for well-characterized and annotated biospecimens from diverse patient populations is essential for understanding disease mechanisms, discovering novel therapeutic targets, and evaluating treatment responses. Additionally, advancements in biobanking technologies, including automation, robotics, and data management systems, are enhancing the efficiency, scalability, and quality of biobanking operations. The increasing adoption of precision medicine approaches and personalized healthcare strategies is driving the demand for biospecimens with detailed molecular and clinical annotations. Biobanks play a pivotal role in supporting precision medicine initiatives by providing researchers and clinicians with access to comprehensive collections of samples for genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. As a result, the Global Biobanks Market is poised for continued expansion, offering significant opportunities for biobanking organizations, healthcare institutions, and life sciences companies to contribute to biomedical research and therapeutic innovation.

Key Market Drivers

Rising Demand for High-Quality Biological Samples

The Global Biobanks Market is experiencing a surge in demand for high-quality biological samples driven by the increasing need for reliable biospecimens in biomedical research, drug development, and clinical applications. High-quality biological samples are essential for studying disease mechanisms, identifying biomarkers, and developing novel therapeutics, making biobanks indispensable resources in the life sciences industry. One of the primary factors fueling the rising demand for high-quality biological samples is the growing emphasis on precision medicine and personalized healthcare. Precision medicine approaches aim to tailor medical treatments to individual patients based on their genetic makeup, lifestyle factors, and environmental influences. As such, there is a heightened need for biospecimens with detailed molecular and clinical annotations to support genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. The increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is driving the demand for biospecimens for disease research and therapeutic development. Biobanks provide researchers and clinicians with access to diverse collections of well-characterized biological samples from various patient populations, enabling the investigation of disease etiology, progression, and treatment responses. Advancements in biobanking technologies have also contributed to the rising demand for high-quality biological samples. Automation, robotics, and data management systems have improved the efficiency, scalability, and reliability of biobanking operations, enabling biobanks to store, process, and manage large volumes of biospecimens and associated data with greater precision and consistency. The increasing adoption of biobanking practices in translational research, clinical trials, and population health studies further drives the demand for high-quality biological samples. Biobanks play a crucial role in facilitating collaborations between academia, industry, and healthcare sectors, fostering innovation and accelerating the development of new diagnostics, therapeutics, and personalized medicine approaches. The rising demand for high-quality biological samples underscores the critical role of biobanks in advancing biomedical research and improving patient care, driving growth and expansion in the Global Biobanks Market.

Advancements in Biobanking Technologies

Advancements in biobanking technologies have revolutionized the landscape of the Global Biobanks Market, enhancing the efficiency, scalability, and reliability of biological sample storage, management, and analysis. These technological innovations have propelled the field of biobanking forward, enabling biobanks to meet the growing demands of researchers, clinicians, and pharmaceutical companies for high-quality biospecimens. One significant advancement in biobanking technology is the implementation of automation and robotics systems. Automated sample handling and processing equipment streamline biobanking workflows, reducing human error, increasing throughput, and improving sample integrity. Robotics platforms enable precise and consistent sample retrieval, aliquoting, and storage, ensuring sample quality and minimizing contamination risks. The advancements in data management systems have revolutionized biobank operations by facilitating efficient sample tracking, inventory management, and data integration. Electronic laboratory information management systems (LIMS) and biobanking software solutions enable real-time monitoring of sample locations, conditions, and associated metadata, ensuring traceability and compliance with regulatory requirements. The innovations in sample preservation and storage technologies have expanded the capabilities of biobanks to store diverse types of biological specimens under optimal conditions. State-of-the-art cryopreservation methods, such as automated liquid nitrogen storage systems and vapor-phase nitrogen freezers, ensure long-term sample viability while minimizing degradation and sample loss. The emerging technologies such as blockchain and artificial intelligence (AI) hold promise for enhancing data security, privacy, and analysis capabilities within the biobanking sector. Blockchain-based systems enable secure and transparent management of sample-related transactions and data sharing, while AI algorithms offer powerful tools for data analysis, pattern recognition, and predictive modeling in biobanking research. The advancements in biobanking technologies are driving innovation, efficiency, and collaboration within the Global Biobanks Market, empowering researchers and clinicians to accelerate biomedical research, drug discovery, and personalized medicine initiatives. Continued investments in technology development and infrastructure are expected to further propel the growth and evolution of the biobanking industry in the years to come.

Growing Prevalence of Chronic Diseases

The growing prevalence of chronic diseases is a significant driver shaping the trajectory of the Global Biobanks Market. Chronic diseases, including cancer, cardiovascular disorders, diabetes, and neurological conditions, pose significant public health challenges worldwide, contributing to a substantial burden of morbidity and mortality. As the incidence of chronic diseases continues to rise globally, there is an increasing need for high-quality biological samples to support research efforts aimed at understanding disease mechanisms, identifying biomarkers, and developing effective treatments. Biobanks play a crucial role in addressing the growing prevalence of chronic diseases by providing researchers, clinicians, and pharmaceutical companies with access to diverse collections of well-characterized biological specimens. These biospecimens, which include blood, tissues, cells, and DNA samples, are essential for studying disease etiology, progression, and treatment responses. For instance, biobanks enable researchers to investigate genetic and environmental factors contributing to the development of chronic diseases, facilitating the discovery of novel biomarkers for early detection, prognosis, and personalized treatment approaches. Additionally, biobanks support translational research efforts by providing access to clinical samples from large and diverse patient populations, enabling the validation of new diagnostic tools and therapeutic interventions. The biobanks play a critical role in supporting longitudinal studies and population health research initiatives aimed at identifying risk factors, trends, and disparities in chronic disease prevalence and outcomes. By collecting and analyzing longitudinal data and biospecimens from individuals over time, biobanks contribute valuable insights into disease trajectories, treatment responses, and long-term health outcomes. The growing prevalence of chronic diseases underscores the importance of biobanking in advancing biomedical research, improving clinical care, and addressing global health challenges. Continued investments in biobank infrastructure, technology, and collaboration are essential for meeting the increasing demand for high-quality biological samples and driving innovation in chronic disease prevention, diagnosis, and treatment.

Key Market Challenges

Sample Quality and Integrity

Sample quality and integrity are paramount in the Global Biobanks Market to ensure the reliability and reproducibility of research findings and clinical applications. Challenges related to sample quality and integrity include the risk of degradation over time, variability in sample collection and processing methods, and the potential for contamination. Maintaining sample quality starts with rigorous adherence to standardized protocols for sample collection, processing, and storage. Proper handling techniques, such as ensuring appropriate temperature control and using preservatives, are essential to minimize degradation and maintain sample integrity. The robust quality control measures, including regular sample monitoring, testing for contamination, and validation of sample identity, are crucial for ensuring the accuracy and reliability of stored samples. Biobanks invest in state-of-the-art infrastructure and employ advanced technologies to safeguard sample quality and integrity. These include automated sample handling systems, stringent quality assurance protocols, and comprehensive data management systems to track sample provenance and ensure compliance with regulatory requirements. By prioritizing sample quality and integrity, biobanks can enhance the utility and value of their repositories, enabling researchers, clinicians, and pharmaceutical companies to access high-quality biological specimens for a wide range of biomedical research and clinical applications.

Data Management and Integration

In the Global Biobanks Market, effective data management and integration are critical for maximizing the utility of biological samples and associated data for research and clinical applications. Biobanks collect and store vast amounts of data, including clinical, genetic, and molecular information, alongside biological specimens. Managing and integrating this diverse array of data presents several challenges. One challenge is the need to establish robust data management systems capable of handling large volumes of data while ensuring security, privacy, and compliance with regulatory requirements. Biobanks must implement advanced data storage, retrieval, and sharing mechanisms to facilitate efficient data management across different research projects and collaborations. The integrating data from disparate sources poses challenges related to data harmonization, standardization, and interoperability. Biobanks must adopt standardized data formats, ontologies, and metadata standards to facilitate data integration and enable cross-study comparisons. Advancements in technologies such as cloud computing, artificial intelligence, and blockchain offer opportunities to enhance data management and integration capabilities within the biobanking sector. These technologies enable real-time data processing, analysis, and sharing, improving data accessibility, collaboration, and knowledge discovery. By addressing challenges related to data management and integration, biobanks can unlock the full potential of their repositories, enabling researchers, clinicians, and policymakers to access comprehensive datasets for advancing biomedical research, drug discovery, and personalized medicine initiatives. Collaborative efforts to establish best practices, standards, and infrastructure for data management and integration are essential for driving innovation and accelerating progress in the field of biobanking.

Key Market Trends

Expansion of Disease-specific Biobanks

The expansion of disease-specific biobanks is a significant trend shaping the Global Biobanks Market. These biobanks focus on collecting, storing, and managing biospecimens from patients with specific diseases or conditions, catering to the specialized needs of researchers and clinicians in targeted research areas. One key driver behind the expansion of disease-specific biobanks is the growing recognition of the heterogeneity and complexity of diseases. By focusing on specific diseases or conditions, these biobanks enable researchers to access well-characterized samples that are relevant to their research interests, facilitating more targeted investigations into disease mechanisms, biomarker discovery, and therapeutic development. The disease-specific biobanks play a crucial role in advancing precision medicine initiatives. By collecting biospecimens from patients with specific diseases, these biobanks contribute to the development of personalized treatment strategies tailored to individual patients' genetic makeup, lifestyle factors, and disease characteristics. For example, cancer biobanks collect tumor samples from patients with different types and stages of cancer, enabling researchers to identify biomarkers associated with treatment response and prognosis and develop targeted therapies. Disease-specific biobanks foster collaboration among researchers, clinicians, and patient advocacy groups focused on specific diseases. By providing a centralized repository of biospecimens and associated clinical data, these biobanks facilitate knowledge sharing, data analysis, and resource pooling, accelerating research progress and improving patient outcomes. The expansion of disease-specific biobanks reflects a growing emphasis on precision medicine, personalized healthcare, and collaborative research initiatives within the Global Biobanks Market. Continued investment in disease-specific biobanking infrastructure, technology, and collaboration is essential for addressing the complex challenges associated with various diseases and driving innovation in biomedical research and clinical care...

Shift towards Virtual Biobanking

The Global Biobanks Market is witnessing a notable shift towards virtual biobanking, a trend characterized by the sharing of data and biospecimens across multiple biobanks and research institutions. Virtual biobanking offers several advantages over traditional, centralized biobanking models, including increased collaboration, data sharing, and resource optimization. One of the key drivers behind the shift towards virtual biobanking is the growing recognition of the need for large, diverse datasets to support biomedical research and personalized medicine initiatives. By enabling researchers to access a wider range of samples and data from multiple biobanks, virtual biobanking facilitates more comprehensive and robust analyses, leading to a deeper understanding of disease mechanisms, biomarker discovery, and therapeutic development. The virtual biobanking promotes collaboration and knowledge exchange among researchers, clinicians, and institutions worldwide. By sharing data and resources, researchers can leverage each other's expertise, infrastructure, and sample collections, accelerating research progress and maximizing the impact of limited resources. Virtual biobanking enables biobanks to overcome logistical and ethical challenges associated with sample sharing. By implementing standardized protocols, data sharing agreements, and quality control measures, virtual biobanks ensure the ethical and responsible use of biospecimens and associated data while protecting patient privacy and confidentiality. Virtual biobanking facilitates data integration and analysis across different research projects and institutions, enabling researchers to perform cross-study comparisons, meta-analyses, and validation studies more efficiently. This approach enhances the reproducibility and generalizability of research findings and promotes transparency and accountability within the scientific community. The shift towards virtual biobanking reflects a growing emphasis on collaboration, data sharing, and innovation in the Global Biobanks Market. Continued investment in virtual biobanking infrastructure, technology, and governance frameworks is essential for realizing the full potential of this transformative approach in advancing biomedical research and improving patient care.

Segmental Insights

Type Insights

Based ontype,disease-oriented biobanks segment dominated the Global Biobanks Market in 2023.This is ascribed to the specialized focus on collecting biospecimens from patients with specific diseases or conditions. This targeted approach facilitates in-depth research into disease mechanisms, biomarker discovery, and therapeutic development, catering to the diverse needs of researchers and clinicians. Disease-oriented biobanks enable precision medicine initiatives by providing well-characterized samples relevant to individual diseases, driving advancements in personalized healthcare. Additionally, the collaborative nature of disease-oriented biobanks fosters partnerships among researchers, clinicians, and patient advocacy groups, further enhancing their prominence in the biobanking landscape.

Application Insights

Based on application, drug discovery segment dominated the Global Biobanks Market in 2023. This is ascribed due to due to the increasing demand for high-quality biological samples to support drug development efforts. Biobanks provide researchers with access to diverse collections of well-characterized biospecimens, enabling the identification of novel drug targets, evaluation of drug efficacy and safety, and optimization of therapeutic interventions. Additionally, advancements in biobanking technologies and collaborations between biobanks and pharmaceutical companies further bolster the role of biobanks in drug discovery. The potential to accelerate the drug development process and bring new treatments to market drives significant investment and focus on the Drug Discovery segment within the Global Biobanks Market.

Regional Insights

North America leads the Global Biobanks Market, due to several factors. The region boasts advanced healthcare infrastructure and significant investments in biomedical research, fostering the establishment of numerous high-quality biobanks. North America is home to many leading pharmaceutical and biotechnology companies, driving demand for biological samples for drug discovery and development. The supportive regulatory frameworks and strong academic and research institutions contribute to the region's leadership in biobanking. The presence of a highly skilled workforce and a culture of innovation further strengthens North America's position in the Global Biobanks Market. Overall, the combination of robust infrastructure, industry expertise, regulatory support, and research capabilities makes North America a dominant player in the biobanking landscape.

Key Market Players

Danaher Corporation

Merck KgaA

Becton, Dickinson, and Company

Avantor, Inc.

Thermo Fisher Scientific, Inc

Tecan Trading AG

QIAGEN N.V.

Hamilton Company

ProMedDx, LLC

ISENET Biobanking S.r.l

Report Scope:

In this report, the Global Biobanks Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Biobanks Market,By Type:

• Disease Oriented Biobanks
• Population Based Biobanks
• Tissue Biobanks
• Others

Global Biobanks Market,By Sample Type:

• Blood Products
• Biological Fluids
• Nucleic Acid
• Cell Lines
• Others

Global Biobanks Market,ByApplication:

• Therapeutics
• Drug Discovery
• Clinical Diagnostics
• Clinical Research

Global Biobanks Market,ByEnd User:

• Academic Research Institutes
• Pharmaceutical Biotechnology Companies
• Hospitals Clinics
• Others

Global Biobanks Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biobanks Market.

Available Customizations:

Global Biobanks Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Biobanks Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks, Others)
  • 5.2.2.By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell Lines, Others)
  • 5.2.3.By Application (Therapeutics, Drug Discovery, Clinical Diagnostics, Clinical Research)
  • 5.2.4.By End User (Academic Research Institutes, Pharmaceutical Biotechnology Companies, Hospitals Clinics, Others)
  • 5.2.5.By Region
  • 5.2.6.By Company (2023)
• 5.3.Market Map
  • 5.3.1.By Type
  • 5.3.2.By Sample Type
  • 5.3.3.By Application
  • 5.3.4.By End User
  • 5.3.5.By Region

6.Asia Pacific Biobanks Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Type
  • 6.2.2.By Sample Type
  • 6.2.3.By Application
  • 6.2.4.By End User
  • 6.2.5.By Country
• 6.3.Asia Pacific: Country Analysis
  • 6.3.1.China Biobanks Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Type
      • 6.3.1.2.2.By Sample Type
      • 6.3.1.2.3.By Application
      • 6.3.1.2.4.By End User
  • 6.3.2.India Biobanks Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Type
      • 6.3.2.2.2.By Sample Type
      • 6.3.2.2.3.By Application
      • 6.3.2.2.4.By End User
  • 6.3.3.Japan Biobanks Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Type
      • 6.3.3.2.2.By Sample Type
      • 6.3.3.2.3.By Application
      • 6.3.3.2.4.By End User
  • 6.3.4.South Korea Biobanks Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Type
      • 6.3.4.2.2.By Sample Type
      • 6.3.4.2.3.By Application
      • 6.3.4.2.4.By End User
  • 6.3.5.Australia Biobanks Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Type
      • 6.3.5.2.2.By Sample Type
      • 6.3.5.2.3.By Application
      • 6.3.5.2.4.By End User

7.Europe Biobanks Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Type
  • 7.2.2.By Sample Type
  • 7.2.3.By Application
  • 7.2.4.By End User
  • 7.2.5.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.France Biobanks Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Type
      • 7.3.1.2.2.By Sample Type
      • 7.3.1.2.3.By Application
      • 7.3.1.2.4.By End User
  • 7.3.2.United Kingdom Biobanks Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Type
      • 7.3.2.2.2.By Sample Type
      • 7.3.2.2.3.By Application
      • 7.3.2.2.4.By End User
  • 7.3.3.Italy Biobanks Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Type
      • 7.3.3.2.2.By Sample Type
      • 7.3.3.2.3.By Application
      • 7.3.3.2.4.By End User
  • 7.3.4.Germany Biobanks Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Type
      • 7.3.4.2.2.By Sample Type
      • 7.3.4.2.3.By Application
      • 7.3.4.2.4.By End User
  • 7.3.5.Spain Biobanks Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Type
      • 7.3.5.2.2.By Sample Type
      • 7.3.5.2.3.By Application
      • 7.3.5.2.4.By End User

8.North America Biobanks Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Type
  • 8.2.2.By Sample Type
  • 8.2.3.By Application
  • 8.2.4.By End User
  • 8.2.5.By Country
• 8.3.North America: Country Analysis
  • 8.3.1.United States Biobanks Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Type
      • 8.3.1.2.2.By Sample Type
      • 8.3.1.2.3.By Application
      • 8.3.1.2.4.By End User
  • 8.3.2.Canada Biobanks Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Type
      • 8.3.2.2.2.By Sample Type
      • 8.3.2.2.3.By Application
      • 8.3.2.2.4.By End User
  • 8.3.3.Mexico Biobanks Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Type
      • 8.3.3.2.2.By Sample Type
      • 8.3.3.2.3.By Application
      • 8.3.3.2.4.By End User

9.South America Biobanks Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Type
  • 9.2.2.By Sample Type
  • 9.2.3.By Application
  • 9.2.4.By End User
  • 9.2.5.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Biobanks Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Type
      • 9.3.1.2.2.By Sample Type
      • 9.3.1.2.3.By Application
      • 9.3.1.2.4.By End User
  • 9.3.2.Argentina Biobanks Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Type
      • 9.3.2.2.2.By Sample Type
      • 9.3.2.2.3.By Application
      • 9.3.2.2.4.By End User
  • 9.3.3.Colombia Biobanks Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Type
      • 9.3.3.2.2.By Sample Type
      • 9.3.3.2.3.By Application
      • 9.3.3.2.4.By End User

10.Middle East and Africa Biobanks Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Type
  • 10.2.2.By Sample Type
  • 10.2.3.By Application
  • 10.2.4.By End User
  • 10.2.5.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Biobanks Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Type
      • 10.3.1.2.2.By Sample Type
      • 10.3.1.2.3.By Application
      • 10.3.1.2.4.By End User
  • 10.3.2.Saudi Arabia Biobanks Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Type
      • 10.3.2.2.2.By Sample Type
      • 10.3.2.2.3.By Application
      • 10.3.2.2.4.By End User
  • 10.3.3.UAE Biobanks Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Type
      • 10.3.3.2.2.By Sample Type
      • 10.3.3.2.3.By Application
      • 10.3.3.2.4.By End User
  • 10.3.4.Egypt Biobanks Market Outlook
    • 10.3.4.1.Market Size Forecast
      • 10.3.4.1.1.By Value
    • 10.3.4.2.Market Share Forecast
      • 10.3.4.2.1.By Type
      • 10.3.4.2.2.By Sample Type
      • 10.3.4.2.3.By Application
      • 10.3.4.2.4.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Recent Developments
• 12.2.Product Launches
• 12.3.Mergers Acquisitions

13.Global Biobanks Market: SWOT Analysis

14.Porter's Five Forces Analysis

• 14.1.Competition in the Industry
• 14.2.Potential of New Entrants
• 14.3.Power of Suppliers
• 14.4.Power of Customers
• 14.5.Threat of Substitute Product

15.Company Profile

• 15.1.Danaher Corporation
  • 15.1.1.Business Overview
  • 15.1.2.Company Snapshot
  • 15.1.3.Products Services
  • 15.1.4.Financials (In case of listed)
  • 15.1.5.Recent Developments
  • 15.1.6.SWOT Analysis
• 15.2.Merck KGaA
• 15.3.Becton, Dickinson, and Company
• 15.4.Avantor, Inc.
• 15.5.Thermo Fisher Scientific, Inc
• 15.6.Tecan Trading AG
• 15.7.QIAGEN N.V.
• 15.8.Hamilton Company
• 15.9.ProMedDx, LLC
• 15.10.ISENET Biobanking S.r.l

16.Strategic Recommendations

17. About Us Disclaimer